Coppen A, Abou-Saleh M T
MRC Neuropsychiatry Research Laboratory, West Park Hospital, Epsom, United Kingdom.
Acta Psychiatr Scand. 1988 Dec;78(6):754-62. doi: 10.1111/j.1600-0447.1988.tb06415.x.
Controlled trials have shown that lithium significantly reduces the morbidity of recurrent affective disorders. We describe here the ongoing affective morbidity in unipolar, bipolar and schizoaffective illness treated primarily by low dosage, once daily lithium, supplemented as necessary by antidepressant or neuroleptic medication. Seventy-eight percent of unipolar patients and 73% of bipolar and schizoaffective patients had no or only slight morbidity during the study year. The treatment was equally effective for both older (age greater than 70 years) and younger patients. Unipolar patients rated as endogenous on the Newcastle Scale had significantly lower morbidity than the nonendogenous patients. Subjective side effects were minimal. These patients, whose untreated morbidity is known to be high, derive considerable benefit from regular supervision in an affective disorder clinic.
对照试验表明，锂能显著降低复发性情感障碍的发病率。我们在此描述主要采用低剂量、每日一次锂盐治疗的单相、双相和分裂情感性疾病患者中持续存在的情感发病率，必要时辅以抗抑郁药或抗精神病药物。在研究年度，78%的单相患者以及73%的双相和分裂情感性患者没有发病或仅有轻微发病。该治疗方法对老年（年龄大于70岁）和年轻患者同样有效。在纽卡斯尔量表上被评定为内源性的单相患者发病率显著低于非内源性患者。主观副作用极小。这些患者已知未经治疗时发病率很高，在情感障碍诊所接受定期监测可从中获益良多。
